Cargando…
A deep sequencing tool for partitioning clearance rates following antimalarial treatment in polyclonal infections
Background and objectives: Current tools struggle to detect drug-resistant malaria parasites when infections contain multiple parasite clones, which is the norm in high transmission settings in Africa. Our aim was to develop and apply an approach for detecting resistance that overcomes the challenge...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4753362/ https://www.ncbi.nlm.nih.gov/pubmed/26817485 http://dx.doi.org/10.1093/emph/eov036 |
_version_ | 1782415851064918016 |
---|---|
author | Mideo, Nicole Bailey, Jeffrey A. Hathaway, Nicholas J. Ngasala, Billy Saunders, David L. Lon, Chanthap Kharabora, Oksana Jamnik, Andrew Balasubramanian, Sujata Björkman, Anders Mårtensson, Andreas Meshnick, Steven R. Read, Andrew F. Juliano, Jonathan J. |
author_facet | Mideo, Nicole Bailey, Jeffrey A. Hathaway, Nicholas J. Ngasala, Billy Saunders, David L. Lon, Chanthap Kharabora, Oksana Jamnik, Andrew Balasubramanian, Sujata Björkman, Anders Mårtensson, Andreas Meshnick, Steven R. Read, Andrew F. Juliano, Jonathan J. |
author_sort | Mideo, Nicole |
collection | PubMed |
description | Background and objectives: Current tools struggle to detect drug-resistant malaria parasites when infections contain multiple parasite clones, which is the norm in high transmission settings in Africa. Our aim was to develop and apply an approach for detecting resistance that overcomes the challenges of polyclonal infections without requiring a genetic marker for resistance. Methodology: Clinical samples from patients treated with artemisinin combination therapy were collected from Tanzania and Cambodia. By deeply sequencing a hypervariable locus, we quantified the relative abundance of parasite subpopulations (defined by haplotypes of that locus) within infections and revealed evolutionary dynamics during treatment. Slow clearance is a phenotypic, clinical marker of artemisinin resistance; we analyzed variation in clearance rates within infections by fitting parasite clearance curves to subpopulation data. Results: In Tanzania, we found substantial variation in clearance rates within individual patients. Some parasite subpopulations cleared as slowly as resistant parasites observed in Cambodia. We evaluated possible explanations for these data, including resistance to drugs. Assuming slow clearance was a stable phenotype of subpopulations, simulations predicted that modest increases in their frequency could substantially increase time to cure. Conclusions and implications: By characterizing parasite subpopulations within patients, our method can detect rare, slow clearing parasites in vivo whose phenotypic effects would otherwise be masked. Since our approach can be applied to polyclonal infections even when the genetics underlying resistance are unknown, it could aid in monitoring the emergence of artemisinin resistance. Our application to Tanzanian samples uncovers rare subpopulations with worrying phenotypes for closer examination. |
format | Online Article Text |
id | pubmed-4753362 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-47533622016-02-16 A deep sequencing tool for partitioning clearance rates following antimalarial treatment in polyclonal infections Mideo, Nicole Bailey, Jeffrey A. Hathaway, Nicholas J. Ngasala, Billy Saunders, David L. Lon, Chanthap Kharabora, Oksana Jamnik, Andrew Balasubramanian, Sujata Björkman, Anders Mårtensson, Andreas Meshnick, Steven R. Read, Andrew F. Juliano, Jonathan J. Evol Med Public Health Original Research Article Background and objectives: Current tools struggle to detect drug-resistant malaria parasites when infections contain multiple parasite clones, which is the norm in high transmission settings in Africa. Our aim was to develop and apply an approach for detecting resistance that overcomes the challenges of polyclonal infections without requiring a genetic marker for resistance. Methodology: Clinical samples from patients treated with artemisinin combination therapy were collected from Tanzania and Cambodia. By deeply sequencing a hypervariable locus, we quantified the relative abundance of parasite subpopulations (defined by haplotypes of that locus) within infections and revealed evolutionary dynamics during treatment. Slow clearance is a phenotypic, clinical marker of artemisinin resistance; we analyzed variation in clearance rates within infections by fitting parasite clearance curves to subpopulation data. Results: In Tanzania, we found substantial variation in clearance rates within individual patients. Some parasite subpopulations cleared as slowly as resistant parasites observed in Cambodia. We evaluated possible explanations for these data, including resistance to drugs. Assuming slow clearance was a stable phenotype of subpopulations, simulations predicted that modest increases in their frequency could substantially increase time to cure. Conclusions and implications: By characterizing parasite subpopulations within patients, our method can detect rare, slow clearing parasites in vivo whose phenotypic effects would otherwise be masked. Since our approach can be applied to polyclonal infections even when the genetics underlying resistance are unknown, it could aid in monitoring the emergence of artemisinin resistance. Our application to Tanzanian samples uncovers rare subpopulations with worrying phenotypes for closer examination. Oxford University Press 2016-01-27 /pmc/articles/PMC4753362/ /pubmed/26817485 http://dx.doi.org/10.1093/emph/eov036 Text en © The Author(s) 2016. Published by Oxford University Press on behalf of the Foundation for Evolution, Medicine, and Public Health. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Research Article Mideo, Nicole Bailey, Jeffrey A. Hathaway, Nicholas J. Ngasala, Billy Saunders, David L. Lon, Chanthap Kharabora, Oksana Jamnik, Andrew Balasubramanian, Sujata Björkman, Anders Mårtensson, Andreas Meshnick, Steven R. Read, Andrew F. Juliano, Jonathan J. A deep sequencing tool for partitioning clearance rates following antimalarial treatment in polyclonal infections |
title | A deep sequencing tool for partitioning clearance rates following antimalarial treatment in polyclonal infections |
title_full | A deep sequencing tool for partitioning clearance rates following antimalarial treatment in polyclonal infections |
title_fullStr | A deep sequencing tool for partitioning clearance rates following antimalarial treatment in polyclonal infections |
title_full_unstemmed | A deep sequencing tool for partitioning clearance rates following antimalarial treatment in polyclonal infections |
title_short | A deep sequencing tool for partitioning clearance rates following antimalarial treatment in polyclonal infections |
title_sort | deep sequencing tool for partitioning clearance rates following antimalarial treatment in polyclonal infections |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4753362/ https://www.ncbi.nlm.nih.gov/pubmed/26817485 http://dx.doi.org/10.1093/emph/eov036 |
work_keys_str_mv | AT mideonicole adeepsequencingtoolforpartitioningclearanceratesfollowingantimalarialtreatmentinpolyclonalinfections AT baileyjeffreya adeepsequencingtoolforpartitioningclearanceratesfollowingantimalarialtreatmentinpolyclonalinfections AT hathawaynicholasj adeepsequencingtoolforpartitioningclearanceratesfollowingantimalarialtreatmentinpolyclonalinfections AT ngasalabilly adeepsequencingtoolforpartitioningclearanceratesfollowingantimalarialtreatmentinpolyclonalinfections AT saundersdavidl adeepsequencingtoolforpartitioningclearanceratesfollowingantimalarialtreatmentinpolyclonalinfections AT lonchanthap adeepsequencingtoolforpartitioningclearanceratesfollowingantimalarialtreatmentinpolyclonalinfections AT kharaboraoksana adeepsequencingtoolforpartitioningclearanceratesfollowingantimalarialtreatmentinpolyclonalinfections AT jamnikandrew adeepsequencingtoolforpartitioningclearanceratesfollowingantimalarialtreatmentinpolyclonalinfections AT balasubramaniansujata adeepsequencingtoolforpartitioningclearanceratesfollowingantimalarialtreatmentinpolyclonalinfections AT bjorkmananders adeepsequencingtoolforpartitioningclearanceratesfollowingantimalarialtreatmentinpolyclonalinfections AT martenssonandreas adeepsequencingtoolforpartitioningclearanceratesfollowingantimalarialtreatmentinpolyclonalinfections AT meshnickstevenr adeepsequencingtoolforpartitioningclearanceratesfollowingantimalarialtreatmentinpolyclonalinfections AT readandrewf adeepsequencingtoolforpartitioningclearanceratesfollowingantimalarialtreatmentinpolyclonalinfections AT julianojonathanj adeepsequencingtoolforpartitioningclearanceratesfollowingantimalarialtreatmentinpolyclonalinfections AT mideonicole deepsequencingtoolforpartitioningclearanceratesfollowingantimalarialtreatmentinpolyclonalinfections AT baileyjeffreya deepsequencingtoolforpartitioningclearanceratesfollowingantimalarialtreatmentinpolyclonalinfections AT hathawaynicholasj deepsequencingtoolforpartitioningclearanceratesfollowingantimalarialtreatmentinpolyclonalinfections AT ngasalabilly deepsequencingtoolforpartitioningclearanceratesfollowingantimalarialtreatmentinpolyclonalinfections AT saundersdavidl deepsequencingtoolforpartitioningclearanceratesfollowingantimalarialtreatmentinpolyclonalinfections AT lonchanthap deepsequencingtoolforpartitioningclearanceratesfollowingantimalarialtreatmentinpolyclonalinfections AT kharaboraoksana deepsequencingtoolforpartitioningclearanceratesfollowingantimalarialtreatmentinpolyclonalinfections AT jamnikandrew deepsequencingtoolforpartitioningclearanceratesfollowingantimalarialtreatmentinpolyclonalinfections AT balasubramaniansujata deepsequencingtoolforpartitioningclearanceratesfollowingantimalarialtreatmentinpolyclonalinfections AT bjorkmananders deepsequencingtoolforpartitioningclearanceratesfollowingantimalarialtreatmentinpolyclonalinfections AT martenssonandreas deepsequencingtoolforpartitioningclearanceratesfollowingantimalarialtreatmentinpolyclonalinfections AT meshnickstevenr deepsequencingtoolforpartitioningclearanceratesfollowingantimalarialtreatmentinpolyclonalinfections AT readandrewf deepsequencingtoolforpartitioningclearanceratesfollowingantimalarialtreatmentinpolyclonalinfections AT julianojonathanj deepsequencingtoolforpartitioningclearanceratesfollowingantimalarialtreatmentinpolyclonalinfections |